KNE:CA:TSV-Kane Biotech Inc (CAD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.13

Change

-0.01 (-7.14)%

Market Cap

USD 0.02B

Volume

0.25M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

+0.02 (+0.79%)

USD 0.19B
ARCH:CA Arch Biopartners Inc

+0.01 (+0.61%)

USD 0.11B
COV:CA Covalon Technologies Ltd.

+0.04 (+1.09%)

USD 0.08B
MIR:CA MedMira Inc

-0.01 (-11.11%)

USD 0.06B
NRX:CA NurExone Biologic Inc.

+0.01 (+1.79%)

USD 0.04B
TTI:CA Thiogenesis Therapeutics Corp.

N/A

USD 0.03B
GSD:CA Devonian Health Group Inc

N/A

USD 0.02B
SBM:CA Sirona Biochem Corp

-0.01 (-14.29%)

USD 0.02B
HEM:CA Hemostemix Inc

N/A

USD 8.28M
RKV:CA Rakovina Therapeutics Inc

N/A

USD 7.22M

ETFs Containing KNE:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 62.50% 69% C- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.50% 69% C- 80% B-
Trailing 12 Months  
Capital Gain 73.33% 76% C+ 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 73.33% 76% C+ 82% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -3.12% 44% F 46% F
Dividend Return -3.12% 44% F 45% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.96% 78% C+ 72% C
Risk Adjusted Return -9.46% 44% F 44% F
Market Capitalization 0.02B 61% D- 66% D+

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector